MBMarta Basaldella

Marta Basaldella

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Marta Basaldella has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Effect of Specialized Psychiatric Assessment and Precision Diagnosis on Pharmacotherapy in Adults with Intellectual Disability

    by Marta Basaldella, Michele Rossi, Marco Garzitto, Roberta Ruffilli, Carlo Francescutti, Shoumitro Deb, Marco Colizzi, Marco O. Bertelli

    Background/Objectives: Adults with intellectual disability (ID) experience high rates of psychiatric comorbidity but often face diagnostic challenges and treatment barriers, leading to inappropriate psychotropic medication use. This study examined the extent to which specialized psychiatric assessment and improved diagnostic accuracy had an impact on medication management and clinical outcomes in adults with ID and co-occurring psychiatric disorders. Methods: This observational retrospective study analyzed medical records from 25 adults with ID who underwent specialized psychiatric assessment at a community-based service in Italy between January 2023 and January 2024. Psychopathological diagnoses were established according to Diagnostic Manual—Intellectual Disability, Second Edition (DM-ID2) criteria, based on clinical observation and a comprehensive assessment using validated instruments. Clinical outcomes were assessed using a psychometric tool encompassing multiple psychopathological and behavioral dimensions. Data on psychotropic prescriptions and side effects were also collected. Non-parametric analyses were performed, with significance set at α = 0.05. Results: The proportion of patients with a psychiatric diagnosis increased from 32% to 96% after specialized assessment (p < 0.001), with notable rises in depressive (0% to 32%), bipolar (8% to 36%), anxiety (4% to 24%), and impulse control (0% to 16%) disorders. First-generation antipsychotic prescriptions decreased (from 36% to 8%, p = 0.023), while antidepressant use increased (from 12% to 52%, p = 0.004). The mean number of side effects per patient declined from 1.6 to 0.5 (p < 0.001), particularly the elevated prolactin level and psychomotor retardation. Significant improvements were observed in symptom intensity and frequency across multiple domains, including aggression, mood disturbances, and compulsions (p < 0.001). Conclusions: In this single-center retrospective study, specialized psychiatric assessment was associated with improved diagnostic accuracy, medication management, and clinical outcomes in adults with ID. The increase in psychiatric diagnoses likely reflects improved identification, addressing key challenges in precision diagnosis for people with neurodevelopmental disorders. Although the overall number of prescribed medications remained stable, optimization of treatment regimens reduced first-generation antipsychotic use and related adverse effects. These findings indicates that access to specialized assessment and precision diagnosis could improve psychopharmacological interventions and outcomes for this vulnerable population, but larger, multi-center and longer-term studies are needed to confirm these results.

  • Open Access

    Effect of Specialized Psychiatric Assessment and Precision Diagnosis On Pharmacotherapy in Adults with Intellectual Disability

    by Marta Basaldella, Michele Rossi, Marco Garzitto, Roberta Ruffilli, Carlo Francescutti, Shoumitro Deb, Marco Colizzi, Marco Bertelli

    Background/Objectives: Adults with intellectual disability (ID) experience high rates of psychiatric comorbidity but often face diagnostic challenges and treatment barriers, often leading to inappropriate psychotropic medication use. This study examined the extent to which specialised psychiatric assessment and improved diagnostic accuracy had an im-pact on medication management and clinical outcomes in adults with ID and co-occurring psychiatric disorders. Methods: This observational retrospective study ana-lysed medical records from 25 adults with ID who underwent specialised psychiatric as-sessment at a community-based service in Italy between January 2023 and January 2024. Psychopathological diagnoses were established according to Diagnostic Manu-al-Intellectual Disability 2nd version (DM-ID2) criteria, based on clinical observation and a comprehensive assessment using validated instruments. Clinical outcomes were as-sessed using a psychometric tool encompassing multiple psychopathological and behav-ioral dimensions. Data on psychotropic prescriptions and side effects were also collected. Non-parametric analyses were performed, with significance set at α=0.05. Results: The proportion of patients with a psychiatric diagnosis increased from 32% to 96% after spe-cialized assessment (p< 0.001), with notable rises in depressive (0% to 32%), bipolar (8% to 36%), anxiety (4% to 24%), and impulse control disorders (0% to 16%). First-generation an-tipsychotic prescriptions decreased (from 36% to 8%, p=0.023), while antidepressant use increased (from 12% to 52%, p=0.004). The mean number of side effects per patient de-clined from 1.6 to 0.5 (p< 0.001), particularly the elevated prolactin level, and psychomotor retardation. Significant improvements were observed in symptom intensity and frequency across multiple domains, including aggression, mood disturbances, and compulsions (p< 0.001). Conclusions: Specialised psychiatric assessment substantially improved diag-nostic accuracy, medication management, and clinical outcomes in adults with ID. The increase in psychiatric diagnoses reflects improved identification, addressing key chal-lenges in precision diagnosis for people with neurodevelopmental disorders. Evi-dence-based medication optimisation reduced inappropriate antipsychotic use and side effects. These findings support the need for specialised assessment and precision diagnosis to improve psycho-pharmacological interventions and outcomes for this vulnerable population.

  • Open Access

    The Supplementation Therapy in Autism and Response to Treatment (START) Study: An Open-Label Feasibility Trial of Ultramicronized Palmitoylethanolamide Potential to Alleviate Psychic Distress among Autistic Adults

    by Riccardo Bortoletto, Marta Basaldella, Anna Candolo, Marco Garzitto, Carla Comacchio, Francesco Curcio, Martina Fabris, Stefano Fornasaro, Fabiana Piscitelli, Orietta Sepulcri, et al.

    Autism spectrum disorder (ASD) is a complex neurodevelopmental condition characterized by impaired social communication and restricted or repetitive behavior and interests. Psychic distress is common among individuals with ASD, especially in its milder form (level 1), with anxiety and depression being the most common types. Recent research has identified neuroinflammation and gut dysbiosis as potential neurobiological mechanisms underlying ASD. Palmitoylethanolamide (PEA), an endocannabinoid (eCB)-like compound, has shown promise in modulating such mechanisms and may thus have therapeutic implications for ASD. To date, no clinical trial has evaluated the efficacy of PEA in adults with ASD. This 12-week open-label study will assess the feasibility, tolerability, safety, and efficacy of ultramicronized PEA (um-PEA) in treating symptoms of psychic distress, such as anxiety and depression, in adults with level 1 ASD. Secondary research endpoints will include um-PEA’s effects on levels of personal autonomy and neurocognitive and interpersonal function. From a biological point of view, this study will assess um-PEA’s effects on inflammatory markers, the metabolic profile, eCB system modulation, and microbial composition as potential mechanisms of action for its therapeutic effect. In conclusion, this study will investigate a novel approach to the treatment of adults presenting with psychic distress in the context of level 1 ASD. The results may provide valuable insight into the use of um-PEA as a treatment option for ASD adults, addressing a significant unmet clinical need.


  • Open Access

    The Italian adaptation of the Mini‐SIPS, a tool for early detection of individuals at clinical high risk and first episode of psychosis: A preliminary study of implementation in an Italian FEP program

    by Maria Ferrara, Marta Basaldella, Francesca Vacca, Scott W. Woods, Barbara C. Walsh, Tyrone D. Cannon, Vinod H. Srihari, Luigi Grassi

    Aims: The study aims are to present the Italian adaptation of the Abbreviated Clinical Structured Interview for DSM‐5 Attenuated Psychosis Syndrome (Mini‐SIPS) and illustrate its implementation in a clinical setting.Methods: The Mini‐SIPS was developed from the original extended version as a tool designed to identify, within the clinical high risk (CHR) framework, the DSM‐5 Attenuated Psychosis Syndrome (APS) and to be implemented in clinical settings. The Mini‐SIPS was translated in Italian by a Yale‐certified SIPS trainer, then back‐translated in English by a trained psychologist, then approved by the Mini‐SIPS authors. Since September 2021, the adapted Italian version of the Mini‐SIPS has been implemented at the First Episode Psychosis (FEP) Program in Ferrara, Italy.Results: The Italian version of Mini‐SIPS was successfully administered to 15 individuals subsequently referred to the First Episode Psychosis service in Ferrara. Within this sample, the tool has proven to be both an effective and efficient tool for the identification of CHR and FEP, and a valid instrument to help with the differential diagnosis. It also performed as a valuable guide for retrieving information about psychiatric history, to date the onset of APS and/or full‐blown psychosis, to track the progression from CHR to psychosis or to symptoms resolution and to describe patients' pathways to care.Conclusion: The Mini‐SIPS is an efficient and easy‐to‐use interview to identify the early stages of psychosis and established psychosis in clinical contexts. The Italian adaptation of this interview could be effectively implemented in other Italian FEP Programs as a screening and monitoring tool. Formal validation of the instrument is needed to assessed validity and reliability in the diagnosis of the CHR and FEP.